American society of clinical oncology statement on minimum standards and exemplary attributes of clinical trial sites

被引:48
作者
Zon, Robin
Meropol, Neal J. [1 ]
Catalano, Robert B.
Schilsky, Richard L.
机构
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
关键词
D O I
10.1200/JCO.2007.15.6398
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To describe both minimum requirements for a site conducting quality clinical trials and attributes of an exemplary site. Methods Minimum requirements and exemplary attributes were selected based on literature review, prevailing regulatory requirements, and consensus among a group of community and academic clinical researchers. Results To provide guidance to oncologists who wish to conduct patient-oriented research, recommendations are made to assist in the development and implementation of high-quality research programs with the priority of protecting the welfare and rights of trial participants. A quality research site complies with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, the accepted international ethical and scientific quality standards for designing, conducting, recording, and reporting trials involving human participants. Recognizing that many research sites conduct clinical trials in compliance with accepted GCP standards, supplemental attributes of an exemplary research site that exceed the GCP criteria are also described. These attributes include diversification of clinical trial mix, high accrual activity, participation in the trial development process, maintenance of high educational standards, quality assurance, multidisciplinary involvement in the clinical trial process, and promotion of clinical trial awareness programs. Conclusion Meeting the minimum criteria ensures conduct of quality clinical trials; however, some sites may wish to incorporate value-added attributes to exceed GCP compliance. These attributes are proposed as performance goals rather than requirements, recognizing that all sites conducting research will not necessarily meet each attribute but may still conduct high-quality clinical trials.
引用
收藏
页码:2562 / 2567
页数:6
相关论文
共 20 条
  • [11] Factors influencing enrollment in clinical trials for cancer treatment
    Klabunde, CN
    Springer, BC
    Butler, B
    White, MS
    Atkins, J
    [J]. SOUTHERN MEDICAL JOURNAL, 1999, 92 (12) : 1189 - 1193
  • [12] Meropol Neal J, 2007, J Natl Compr Canc Netw, V5, P655
  • [13] Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors
    Mills, EJ
    Seely, D
    Rachlis, B
    Griffith, L
    Wu, P
    Wilson, K
    Ellis, P
    Wright, JR
    [J]. LANCET ONCOLOGY, 2006, 7 (02) : 141 - 148
  • [14] *NAT CANC I, STAND CAS REP FORM C
  • [15] *NAT CANC I, REP CLIN TRIALS WORK
  • [16] National Cancer Institute, BEST PRACT BIOSP RES
  • [17] nccn, 2021 NCCN Adult Cancer Pain. Version 1.2021, 02/26/2021 © 2021 National Comprehensive Cancer Network® (NCCN®). NCCN Clinical Practice Guidelines in Oncology-Adult Cancer Pain. (2021 Version2)
  • [18] SUSAN B, KOMEN BREAST CANC FD
  • [19] *US FED GOVT, 1949, TRIALS WAR CRIM NUR, V2, P181
  • [20] World Medical Association, World Medical Association Declaration of Helsinki-ethical principles for scientific requirements and research protocols